Effects and cautions
KLOW peptide safety still has unanswered questions
I’d like a tidy list of known benefits and side effects too. The problem is that the four-part blend hasn’t had controlled human testing, so that list doesn’t exist.

A little human data isn’t a complete safety picture
A BPC-157 infusion pilot in two adults reported no observed adverse events. Two people receiving one ingredient can’t establish long-term safety for KLOW or reveal uncommon problems.
For TB-500, FDA found no published human administration study. Studies of the larger protein thymosin beta-4 don’t fill that gap: TB-500 is a smaller fragment.
No controlled study establishes how all four ingredients behave together in people. That leaves safety questions about the mixture itself, as well as questions about each ingredient.
Why the immune system comes up
FDA’s BPC-157 review flags possible immune reactions. That means the body might respond to the peptide as an invader. Impurities and clumped material can add to the concern.
The KPV review also describes missing basic safety tests. These are reasons for caution, rather than measured rates of harm from KLOW.
I can’t give a dependable percentage for the blend’s risks. Missing evidence doesn’t establish safety, and it doesn’t prove that a particular serious reaction will happen.
Personal details can change the questions
GHK-Cu carries copper. A condition that affects copper handling, such as Wilson disease, raises a theoretical concern. KLOW hasn’t been studied in people with that condition.
BPC-157 research in cells and animals explores new blood-vessel growth. Tumours also need a blood supply, which raises a theoretical question around active or recent cancer. This doesn’t demonstrate that KLOW causes cancer or establish safety for someone with cancer.
KPV changes inflammatory signals in lab studies. What that means during an active infection or with autoimmune disease remains a theoretical concern, rather than a demonstrated KLOW effect. The blend has no human study answering those questions.
Sport brings a separate issue: thymosin beta-4 and its derivatives, including TB-500, are prohibited under anti-doping rules. That status isn’t a measurement of medical risk.
On FDA’s page current as of April 22, 2026, BPC-157, KPV, TB-500 and injectable GHK-Cu are “nominated but withdrawn.” The people seeking consideration withdrew their requests; FDA’s safety concerns remain. Withdrawal isn’t approval or permission to compound.
The prescription notes explain why an individual care decision and an established safety record are different things.